 Home > Medical News > Latest Medical News > The targeted anticancer drug Pepaxto is included in the NCCN clinical practice guidelines for multiple myeloma in the United States

The targeted anticancer drug Pepaxto is included in the NCCN clinical practice guidelines for multiple myeloma in the United States

 Last Update: 2021-03-27
 Source: Internet
 Author: User

Tags

cancer diet cure

national lead company

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Oncopeptipes AB is a pharmaceutical company specializing in targeted therapies for refractory blood diseases.

On February 26, 2021, Pepaxto received accelerated approval from the US FDA for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone.

It is particularly worth mentioning that Pepaxto (melflufen) is the first anti-cancer peptide-drug conjugate (PDC) approved by the US FDA.

NCCN is an alliance of 30 cancer centers in the United States.

Melflufen is activated by aminopeptidase, which is present in all human cells but is overexpressed in many cancers, including myeloma.

Pepaxto's approval is based on the results of the pivotal Phase II HORIZON study.

The results showed that among the 97 patients, the overall response rate (ORR) was 23.

Conclusion: The combination of melflufen and dexamethasone will provide an important treatment option for adult patients with relapsed or refractory MM who are difficult to treat and have a poor prognosis, including three-drug refractory myeloma patients and extramedullary diseases (EMD).

Original source: Oncopeptides Announces National Comprehensive Cancer Network? Adds PEPAXTO? (melphalan flufenamide) to Its Multiple Myeloma Clinical Practice Guidelines

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.